SK Capital Teaming Up with IBA

SK Capital Partners has entered into an agreement to acquire a 60% stake in a new company, IBA Molecular Imaging, which is being derived from the radiopharmaceutical division of Ion Beam Applications (IBA). IBA will own a 40% stake in the new company. The transaction is valued at approximately €180 million ($228.62 million).